厄贝沙坦联合卡托普利治疗高血压并发微量白蛋白尿患者疗效观察

目的:观察厄贝沙坦和卡托普利联合治疗高血压并发微量白蛋白尿患者的降压效果和减少尿微量白蛋白效果。方法:采用随机分组对照法将84例原发性高血压病并发微量白蛋白尿患者分为三组:厄贝沙坦治疗组26例;卡托普利治疗组28例;厄贝沙坦联合卡托普利治疗组30例。观察4周,收集血压、尿素氮、尿微量白蛋白等指标。结果:三组均能显著降低血压和尿微量白蛋白,但联合治疗组较任一单用组更显著减少了尿微量白蛋白(P<0.05)。结论:厄贝沙坦与卡托普利联合治疗高血压并发微量蛋白尿患者不但能有效的控制高血压还具有显著的肾功能保护作用。

The clinical investigation of the combination of irbesartan and captopril on hypertensive patients with microalbuminuria

Objective:To study the therapeutic effects of the combination of irbesartan and captopril in 84 hypertensive patients with microalbuminuria.Method:In this study,84 hypertensive patients with microalbuminuria were divided into three groups according to the anti-hypertension drugs.26 patients were treated with irbesartan;28 patients were treated with captopril and 30 patients were treated with irbesartan and captopril.The antihypertension effect and the UREP after the treatment were compared in these three groups.Result:Patients in the three groups have similar anti-hypertension effect,but the UREP of the combination group is better than the other two group,(P<0.05)。Conclusion:The combination of irbesartan and captopril is better than single use in the protection renal function.